

INDIVIDUAL LABORATORY REPORT (ILR) - Lab 1310

SCHEME: LUNG CANCER (NSCLC)

SEASON: 2018

Case 1		
Assessment Category	Score ¹	Comments (& deductions ²)
Genotyping	2.00	No deduction (0)
Interpretation	2.00	As your testing strategy only included EGFR, you have not detected the BRAF c. 1799T>A p.(Val600Glu) variant present in this sample. It should be noted that approximately 3% of NSCLC patients have this variant and whilst there is currently no available licenced targeted therapy for BRAF in NSCLC in many countries, the FDA has already granted regular approval to dabrafenib and trametinib in combination for metastatic NSCLC with BRAF V600E mutation. We therefore recommend that you consider developing the capability to test for BRAF in NSCLC. (0)
Patient Identifiers & Clerical Accuracy	2.00	No deduction (0)

Case 2		
Assessment Category	Score ¹	Comments (& deductions ²)
Genotyping	2.00	No deduction (0)
Interpretation	2.00	As your testing strategy only included EGFR, including a comment that testing of other targetable genes e.g. BRAF, ROS/ALK may be advised in line with Best Practice guidelines. (0)
Patient Identifiers & Clerical Accuracy	2.00	No deduction (0)

Case 3		
Assessment Category	Score ¹	Comments (& deductions ²)
Genotyping	2.00	No deduction (0)
Interpretation	2.00	No deduction (0)
Patient Identifiers & Clerical Accuracy	2.00	No deduction (0)

Case 4		
Assessment Category	Score ¹	Comments (& deductions ²)
Genotyping	2.00	No deduction (0)

Case 5		
Assessment Category	Score ¹	Comments (& deductions ²)
Genotyping	2.00	No deduction (0)

Case 6		
Assessment Category	Score ¹	Comments (& deductions ²)
Genotyping	2.00	No deduction (0)

This report is provisional pending the outcome of the appeals process

¹ Maximum score is 2.00

² Deductions from the maximum score

³ Green >= Scheme mean, Orange < Scheme mean, Red Poor performance.

NRS no results submitted. WDS withdrew from scheme

Case 7		
Assessment Category	Score ¹	Comments (& deductions ²)
Genotyping	2.00	No deduction (0)

Case 8		
Assessment Category	Score ¹	Comments (& deductions ²)
Genotyping	2.00	No deduction (0) There is also an EGFR c.2390G>C p.(Cys797Ser) variant present in exon 20 of this sample at 15% VAF that is not detected by the commercial kit used.

Case 9		
Assessment Category	Score ¹	Comments (& deductions ²)
Genotyping	2.00	No deduction (0)

Case 10		
Assessment Category	Score ¹	Comments (& deductions ²)
Genotyping	2.00	No deduction (0)

General Comments	Thank you for participating in this year's EQA scheme. We look forward to you joining us in the 2019 scheme - registration is now open - please see the EMQN website
-------------------------	--

SUMMARY OF YOUR PERFORMANCE IN THIS SCHEME

Assessment Category

Genotyping

Interpretation


Patient Identifiers & Clerical Accuracy


Scheme result (SATISFACTORY or POOR)

Performance ³ (mean score)
2.00
2.00
2.00
SATISFACTORY

Report approved and authorised by Simon Patton (09 November 2018) on behalf of EMQN.

Signed:




2018.12.25

This report is provisional pending the outcome of the appeals process

¹ Maximum score is 2.00

² Deductions from the maximum score

³ Green >= Scheme mean, Orange < Scheme mean, Red Poor performance.

NRS no results submitted. WDS withdrew from scheme